Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease by Silvio Danese, Andrew Beaton, Elizabeth A. Duncan, Anne-Kristina Mercier, Jessica Neisen, Henrik Seth, Sofia Zetterstrand, Bruce E. Sands

Get full text